Business Description
Jiangsu Kanion Pharmaceutical Co Ltd
NAICS : 325412
ISIN : CNE000001CL7
Share Class Description:
SHSE:600557: Class ACompare
Compare
Traded in other countries / regions
600557.China IPO Date
2002-09-18Description
Jiangsu Kanion Pharmaceutical Co Ltd focuses on R&D, production and trade of traditional Chinese medicine. The company also makes orthopedics, cardiovascular, anti-infective and anti-tumor products.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.75 | |||||
| Interest Coverage | 631.14 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 5.57 | |||||
| Beneish M-Score | -2.64 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 18.5 | |||||
| 3-Year EBITDA Growth Rate | 17 | |||||
| 3-Year EPS without NRI Growth Rate | 22.3 | |||||
| 3-Year FCF Growth Rate | 14.6 | |||||
| 3-Year Book Growth Rate | 8.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 14.28 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 6.91 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 70.66 | |||||
| 9-Day RSI | 61.12 | |||||
| 14-Day RSI | 57.58 | |||||
| 3-1 Month Momentum % | 27.51 | |||||
| 6-1 Month Momentum % | -8.52 | |||||
| 12-1 Month Momentum % | -17.45 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.6 | |||||
| Quick Ratio | 2.22 | |||||
| Cash Ratio | 1.49 | |||||
| Days Inventory | 138.73 | |||||
| Days Sales Outstanding | 54.02 | |||||
| Days Payable | 68.35 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.45 | |||||
| Dividend Payout Ratio | 0.4 | |||||
| 3-Year Dividend Growth Rate | 40.1 | |||||
| Forward Dividend Yield % | 2.45 | |||||
| 5-Year Yield-on-Cost % | 2.42 | |||||
| 3-Year Average Share Buyback Ratio | 0.5 | |||||
| Shareholder Yield % | 2.46 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 74.67 | |||||
| Operating Margin % | 11.03 | |||||
| Net Margin % | 12.15 | |||||
| FCF Margin % | 11.32 | |||||
| ROE % | 10.54 | |||||
| ROA % | 7.74 | |||||
| ROIC % | 15.7 | |||||
| 3-Year ROIIC % | -17.29 | |||||
| ROC (Joel Greenblatt) % | 20.47 | |||||
| ROCE % | 9.44 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 16.33 | |||||
| Forward PE Ratio | 13.94 | |||||
| PE Ratio without NRI | 16.33 | |||||
| Shiller PE Ratio | 21.1 | |||||
| Price-to-Owner-Earnings | 29.95 | |||||
| PEG Ratio | 81.65 | |||||
| PS Ratio | 2.01 | |||||
| PB Ratio | 1.72 | |||||
| Price-to-Tangible-Book | 1.86 | |||||
| Price-to-Free-Cash-Flow | 17.75 | |||||
| Price-to-Operating-Cash-Flow | 10.28 | |||||
| EV-to-EBIT | 12.95 | |||||
| EV-to-EBITDA | 12.95 | |||||
| EV-to-Revenue | 1.49 | |||||
| EV-to-FCF | 13.06 | |||||
| Price-to-GF-Value | 0.85 | |||||
| Price-to-Projected-FCF | 0.91 | |||||
| Price-to-Median-PS-Value | 0.86 | |||||
| Price-to-Graham-Number | 1.17 | |||||
| Price-to-Net-Current-Asset-Value | 4.49 | |||||
| Price-to-Net-Cash | 22.81 | |||||
| Earnings Yield (Greenblatt) % | 7.72 | |||||
| FCF Yield % | 5.74 | |||||
| Forward Rate of Return (Yacktman) % | 9.79 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Jiangsu Kanion Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 4,481.312 | ||
| EPS (TTM) (Â¥) | 0.93 | ||
| Beta | 1.13 | ||
| 3-Year Sharpe Ratio | 0.42 | ||
| 3-Year Sortino Ratio | 0.72 | ||
| Volatility % | 44.85 | ||
| 14-Day RSI | 57.58 | ||
| 14-Day ATR (Â¥) | 0.453003 | ||
| 20-Day SMA (Â¥) | 14.752 | ||
| 12-1 Month Momentum % | -17.45 | ||
| 52-Week Range (Â¥) | 11.77 - 24.09 | ||
| Shares Outstanding (Mil) | 581.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Jiangsu Kanion Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Jiangsu Kanion Pharmaceutical Co Ltd Stock Events
| Event | Date | Price (Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Jiangsu Kanion Pharmaceutical Co Ltd Frequently Asked Questions
What is Jiangsu Kanion Pharmaceutical Co Ltd(SHSE:600557)'s stock price today?
The current price of SHSE:600557 is ¥15.28. The 52 week high of SHSE:600557 is ¥24.09 and 52 week low is ¥11.77.
When is next earnings date of Jiangsu Kanion Pharmaceutical Co Ltd(SHSE:600557)?
The next earnings date of Jiangsu Kanion Pharmaceutical Co Ltd(SHSE:600557) is .
Does Jiangsu Kanion Pharmaceutical Co Ltd(SHSE:600557) pay dividends? If so, how much?
The Dividend Yield %  of Jiangsu Kanion Pharmaceutical Co Ltd(SHSE:600557) is 2.45% (As of Today), Highest Dividend Payout Ratio of Jiangsu Kanion Pharmaceutical Co Ltd(SHSE:600557) was 0.4. The lowest was 0.09. And the median was 0.14. The  Forward Dividend Yield % of Jiangsu Kanion Pharmaceutical Co Ltd(SHSE:600557) is 2.45%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers